Literatura académica sobre el tema "Prognostic markers"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Prognostic markers".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Prognostic markers"
Kovaleva, Olga V., Madina A. Rashidova, Daria V. Samoilova, Polina A. Podlesnaya, Rasul M. Tabiev, Valeria V. Mochalnikova y Alexei Gratchev. "CHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer". International Journal of Molecular Sciences 22, n.º 1 (5 de enero de 2021): 450. http://dx.doi.org/10.3390/ijms22010450.
Texto completoTaha, Anas, Stephanie Taha-Mehlitz, Stephanie Petzold, Sergey L. Achinovich, Dmitry Zinovkin, Bassey Enodien, Md Zahidul I. Pranjol y Eldar A. Nadyrov. "Prognostic Value of Immunohistochemical Markers for Locally Advanced Rectal Cancer". Molecules 27, n.º 3 (18 de enero de 2022): 596. http://dx.doi.org/10.3390/molecules27030596.
Texto completoElias, Jules M. "The Prognosis of Prognostic Markers. Quo Vadis?" Journal of Histotechnology 19, n.º 1 (marzo de 1996): 7–8. http://dx.doi.org/10.1179/his.1996.19.1.7.
Texto completoVeryaskina, Yuliya Andreevna, Sergei Evgenievich Titov, Igor Borisovich Kovynev, Tatiana Ivanovna Pospelova y Igor Fyodorovich Zhimulev. "Prognostic Markers of Myelodysplastic Syndromes". Medicina 56, n.º 8 (27 de julio de 2020): 376. http://dx.doi.org/10.3390/medicina56080376.
Texto completoChen, LangXiong, XiaoSong He, ShiJiang Yi, GuanCheng Liu, Yi Liu y YueFu Ling. "Six Glycolysis-Related Genes as Prognostic Risk Markers Can Predict the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma". BioMed Research International 2021 (10 de febrero de 2021): 1–13. http://dx.doi.org/10.1155/2021/8824195.
Texto completoAlieva, A. M., A. V. Sozykin, N. V. Teplova, E. V. Reznik, D. V. Izimarieva, N. A. Novikova, I. V. Lozovsky, Е. E. Averin, R. K. Valiev y I. G. Nikitin. "Tenascin-C as a cardiovascular marker". Russian Journal of Cardiology 27, n.º 8 (3 de septiembre de 2022): 5150. http://dx.doi.org/10.15829/1560-4071-2022-5150.
Texto completoLabussiere, Marianne, Xiao-Wei Wang, Ahmed Idbaih, François Ducray y Marc Sanson. "Prognostic markers in gliomas". Future Oncology 6, n.º 5 (mayo de 2010): 733–39. http://dx.doi.org/10.2217/fon.10.25.
Texto completoPerkins, Geraldine, Pierre Laurent-Puig y Julien Taieb. "Ampullary carcinoma prognostic markers". Oncotarget 10, n.º 44 (16 de julio de 2019): 4509–10. http://dx.doi.org/10.18632/oncotarget.27067.
Texto completoBakhshi, Sameer y Venkatraman Radhakrishnan. "Prognostic markers in osteosarcoma". Expert Review of Anticancer Therapy 10, n.º 2 (febrero de 2010): 271–87. http://dx.doi.org/10.1586/era.09.186.
Texto completoRoss, Jeffrey S., Christine E. Sheehan, Hugh AG Fisher, Ronald A. Kauffman, Eric M. Dolen y Bhaskar VS Kallakury. "Prognostic markers inprostate cancer". Expert Review of Molecular Diagnostics 2, n.º 2 (marzo de 2002): 129–42. http://dx.doi.org/10.1586/14737159.2.2.129.
Texto completoTesis sobre el tema "Prognostic markers"
Oguejiofor, Kenneth Kenechukwu. "Prognostic markers in oropharyngeal cancers". Thesis, University of Manchester, 2016. https://www.research.manchester.ac.uk/portal/en/theses/prognostic-markers-in-oropharyngeal-cancers(fda96224-657d-4049-ae6c-50db33a5388a).html.
Texto completoBlonski, Katharina. "Glycoconjugates as prognostic markers in ovarian cancer". [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=975965115.
Texto completoSalih, Tamir. "Prognostic and predictive markers in oesophageal cancer". Thesis, University of Leeds, 2015. http://etheses.whiterose.ac.uk/15196/.
Texto completoDouglas, Catriona Mairi. "Prognostic markers in head and neck cancer". Thesis, University of Manchester, 2011. http://www.manchester.ac.uk/escholar/uk-ac-man-scw:130436.
Texto completoLaird, Alexander. "Molecular prognostic markers in renal cell carcinoma". Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/17873.
Texto completoSevov, Marie. "RNA-based Prognostic Markers in Chronic Lymphocytic Leukemia". Doctoral thesis, Uppsala universitet, Institutionen för genetik och patologi, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-133250.
Texto completoWhiteside, Michael C. R. "Genetic markers for prognostic prediction in colorectal cancer". Thesis, Queen's University Belfast, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.387972.
Texto completoKawesha, Anthony. "Prognostic molecular markers in resected ductal pancreatic carcinoma". Thesis, University of Birmingham, 2017. http://etheses.bham.ac.uk//id/eprint/7596/.
Texto completoMartins, Ana Teresa Pinto Teixeira. ""Prognostic Value Of Methilation Markers In Breast Cancer"". Master's thesis, Instituto de Ciências Biomédicas Abel Salazar, 2008. http://hdl.handle.net/10216/20022.
Texto completoBur, H. (Hamid). "Biological prognostic and predictive markers in Hodgkin lymphoma". Doctoral thesis, Oulun yliopisto, 2018. http://urn.fi/urn:isbn:9789526219455.
Texto completoTiivistelmä Hodgkinin lymfooma (engl. HL) kuuluu heterogeeniseen imukudossyöpien eli lymfoomen ryhmään. Yli 80 % lymfoomapotilaista voidaan parantaa solunsalpaaja- ja sädehoidon avulla. Hyvän ennusteen takia HL- tutkimuksen tärkeä painopiste on säde- ja solunsalpaajahoidon pitkän ajan haittavaikutukset. Huomattava määrä potilaista kärsii tai jopa kuolee hoitoon liittyvistä pitkäaikaishaitoista johtuen. Tämän tutkimuksen tarkoituksena oli löytää uusia mahdollisia biologisia tekijöitä, jotka ennakoisivat taudin huonoa ennustetta ja samalla antaa uusia näkökulmia HL potilaiden hoidon yksilöllistämiseen. Tämä retrospektiivinen tutkimus käsitti vuosina 1997-2015 samanlaisesti hoidettuja Hodgkinin lymfooma -potilaita. Immunohistokemiallisilla värjäyksillä määritettiin biologisten merkkiaineiden, mukaan lukien oksidatiivisen stressin markkereiden 8- hydroksideoksiguanosiinin (8-OHdG) ja nitrotyrosiinin, sekä antioksidanttientsyymien mangaanisuperoksidi-dismutaasin (MnSOD) sekä peroksiredoksiinien (Prx II, Prx III, Prx V, Prx VI) ilmentymistä HL -potilasnäytteissä. Määrittelimme myös immunohistokemiallisilla värjäyksillä epigeneettisten säätelijöiden lysiinin spesifisen demetylaasientsyymin 4 (KDM4A, KDM4B, KDM4D) sekä sirtuiinien (SIRT1, SIRT4, SIRT6), hypoksiaa indusoivien tekijöiden (HIF-1α, HIF-2α), prolyylihydroksylaasientsyymien (PHD1, PHD2, PHD3) ja DNA:ta korjaavien proteiinien Rap1 vaikuttuvan tekijä 1 (Rif1) ja O6-metyyliguaniini-DNA metyylitransferaasin (MGMT) ilmentymistä edustavissa klassista Hodgkinin lymfoomaa sairastavien potilaiden (engl. cHL) näytteissä. Heikko 8-OHdG värjäytyminen ennusti ennenaikaista taudin uusiutumaa levinneessä HL:ssa ja korkea MnSOD ilmaantuvuus ennusti ennenaikaista taudin uusiutumaa koko HL -ryhmässä. Sädehoidetuilla cHL potilailla voimakas PHD1, KDM4B ja KDM4D värjäytyminen ennusti ennenaikaista taudin uusiutumaa. Tulokset osoittivat myös, että erityisesti sädehoidetuilla levinneen taudin cHL potilailla voimakas HIF-1α, SIRT6, Rif1 ja SIRT6 yhdessä Rif1:n kanssa oli yhteydessä pidentyneeseen uusiutumavapaaseen aikaan. Monimuuttuja-analyysissä PHD1, MnSOD, 8-OHdG ja Rif1 itsenäisenä ja yhdessä SIRT6 kanssa ennustivat tilastollisesti merkitsevästi taudin ennenaikaista uusiutumaa. Tulokset osoittavat näiden eri biomarkkereiden merkittävyyden HL:ssä, erityisesti sädehoitoa saaneilla potilailla. Tuloksista voi olla hyötyä, kun hoitokäytäntöjä yksilöidään, mikä voisi helpottaa välttämään liiallista hoitoa ja hallitsemaan pitkäaikaisiin hoitoihin liittyviä haittoja. Näiden alustavien havaintojen vahvistamiseksi tarvitaan kuitenkin lisätutkimuksia
Libros sobre el tema "Prognostic markers"
CNS cancer: Models, markers, prognostic factors, targets, and therapeutic approaches. Central nervous system cancer: Humana Press, 2009.
Buscar texto completoDiagnostic and prognostic biomarkers and therapeutic targets in melanoma. Totowa, N.J: Humana, 2012.
Buscar texto completoMcNamara, M. Morphologic and molecular markers of prognosis in ocular melanoma. Dublin: University College Dublin, 1997.
Buscar texto completoHughes, Mark D. Point-of-care testing: Status and prognosis. Waltham, MA: Decision Resources, 1996.
Buscar texto completoLeckey, Joan Lesley. Urinary and tumour markers of disease recurrence and prognosis in transitional cell carcinoma of the bladder. [s.l: The Author], 1997.
Buscar texto completoGiampietro, Gasparini y Hayes Daniel 1951-, eds. Biomarkers in breast cancer: Molecular diagnostics for predicting and monitoring therapeutic effect. Totowa, N.J: Humana Press, 2006.
Buscar texto completoInternational Falk Workshop (1995 Basel, Switzerland). Surrogate markers to assess efficacy of treatmentin chronic liver diseases: Proceedings of the International Falk Workshop held in Basel, Switzerland, October 23-24, 1995. Dordrecht: Kluwer Academic, 1996.
Buscar texto completoPrognostic Markers in Hematologic Oncology. Informa Healthcare, 2005.
Buscar texto completoNew Prognostic and Predictive Markers in Cancer Progression. MDPI, 2021. http://dx.doi.org/10.3390/books978-3-03943-978-2.
Texto completoLau, Suzanne Kit-Yan. Validation of putative prognostic markers for non-small cell lung carcinoma. 2007.
Buscar texto completoCapítulos de libros sobre el tema "Prognostic markers"
Bahler, David. "Prognostic Markers". En Molecular Pathology Library, 65–72. Boston, MA: Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-5698-9_3.
Texto completoSchuh, Anna. "Prognostic Markers". En Hematologic Malignancies, 53–65. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-11392-6_4.
Texto completoSienko, Anna, Timothy Craig Allen y Philip T. Cagle. "Prognostic Markers". En Molecular Pathology Library, 193–99. New York, NY: Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-72430-0_18.
Texto completoRhodes, A., P. J. Newman y E. D. Bennett. "Prognostic Markers in Sepsis". En Yearbook of Intensive Care and Emergency Medicine, 238–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-72038-3_21.
Texto completoHabuchi, Tomonori. "Prognostic Markers for Bladder Cancer". En Bladder Tumors:, 139–63. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-928-4_8.
Texto completoGarcia, Agustin A. y Nazish Ahmad. "Prognostic Markers in Breast Cancer". En Biomarkers in Oncology, 25–42. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-9755-5_2.
Texto completoDavies, Janine M. y Howard L. McLeod. "Prognostic Markers in Colon Cancer". En Biomarkers in Oncology, 131–62. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-9755-5_7.
Texto completoSelvi, Radhakrishna. "Breast Pathology: Conventional Prognostic Markers". En Breast Diseases, 229–31. New Delhi: Springer India, 2014. http://dx.doi.org/10.1007/978-81-322-2077-0_25.
Texto completoGlimelius, Bengt. "Prognostic factors including clinical markers". En Cancer Treatment and Research, 89–96. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-1739-5_6.
Texto completoChristenson, Robert H. y Hassan M. E. Azzazy. "Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers". En Cardiac Markers, 59–86. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1007/978-1-59259-385-9_4.
Texto completoActas de conferencias sobre el tema "Prognostic markers"
Pinho, Rafaela Seixas, Afonso Moraes Melo Junior, Rafael Silva Lemos, Amanda da Silva Furtado y Luís Eduardo Werneck de Carvalho. "Gliomas: tumor markers and prognosis". En XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.538.
Texto completo"Rational Identification of Prognostic Markers of Breast Cancer". En International Conference on Bioinformatics Models, Methods and Algorithms. SCITEPRESS - Science and and Technology Publications, 2014. http://dx.doi.org/10.5220/0004915202650270.
Texto completoWilliams, Jennie L. y Ping Ji. "Abstract A54: miRNA profiling: prognostic markers in chemoprevention". En Abstracts: AACR International Conference on the Science of Cancer Health Disparities‐‐ Sep 30-Oct 3, 2010; Miami, FL. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1055-9965.disp-10-a54.
Texto completoRoth, S., R. M'pembele, A. Stroda, C. Jansen, G. Lurati Buse, I. Tudorache, U. Boeken et al. "New Prognostic Markers for Patients Undergoing VA-ECMO". En 51st Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1742846.
Texto completoLima, Beatriz Alves, Andressa da Silva Pereira, Bruna Alves Lima, Diana Gonçalves Lima, Leonardo Ferreira Pucci, Renato Moraes Ferreira, Tiago Castro Ferreira y Henrique Ferreira Pucci. "PREDICTORS OF BREAST CANCER PROGNOSIS BASED ON TUMOR BIOMARKERS". En Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2022.
Texto completoFoerster, Y., M. Diensthuber, S. Balster, J. Gabrielpillai, H. Petzold, J. Wagenblast, T. Stöver y C. Geißler. "Neurotrophin receptors - prognostic markers and therapeutic targets for HNSCC?" En Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1710952.
Texto completoGeißler, C., Y. Foerster, M. Diensthuber, J. Wagenblast, S. Balster, J. Gabrielpillai, H. Petzold y T. Stöver. "Neurotrophin receptors- prognostic markers and therapeutic targets for HNSCC?" En 100 JAHRE DGHNO-KHC: WO KOMMEN WIR HER? WO STEHEN WIR? WO GEHEN WIR HIN? Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1727956.
Texto completoAchaiah, Andrew, Andrea Pereira, Harriet Bothwell, Kritica Dwivedi, Armila Rathnapala, Rosia Barker, Valentina Iotchkova, Rachel Hoyles y Ling-Pei Ho. "Blood leukocyte levels as potential prognostic markers in IPF". En ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa388.
Texto completoKujawa, Katarzyna A., Ewa Zembala-Nożyńska, Alexander J. Cortez, Jolanta Kupryjańczyk y Katarzyna M. Lisowska. "423 Fibronectin and periostin as prognostic markers in ovarian cancer". En ESGO SoA 2020 Conference Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-esgo.136.
Texto completoStetson, Lindsay C., Quinn T. Ostrom, Peter Liao, Andrew E. Sloan, Mark R. Chance y Jill S. Barnholtz-Sloan. "Abstract 4220: Heterogeneous distribution of prognostic protein markers in glioblastoma". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4220.
Texto completoInformes sobre el tema "Prognostic markers"
Lapointe, Jacques. Identification of Prostate Cancer Prognostic Markers. Fort Belvoir, VA: Defense Technical Information Center, octubre de 2013. http://dx.doi.org/10.21236/ada595253.
Texto completoGullapalli, Rao P. Investigation of Prognostic Ability of Novel Imaging Markers for Traumatic Brain Injury (TBI). Fort Belvoir, VA: Defense Technical Information Center, octubre de 2011. http://dx.doi.org/10.21236/ada577060.
Texto completoGilcrease, Michael Z. Investigation of Alpha6 Integrins and Their Signaling Intermediate as Prognostic Markers for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, mayo de 2002. http://dx.doi.org/10.21236/ada407363.
Texto completoGilcrease, Michael Z. Investigation of Alpha6 Integrins and Their Signaling Intermediates as Prognostic Markers for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, mayo de 2004. http://dx.doi.org/10.21236/ada425749.
Texto completoKeyomarsi, Khandan. Cyclin E, A Potential Prognostic Marker in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, octubre de 1998. http://dx.doi.org/10.21236/ada368551.
Texto completoKeyomarsi, Khandan. Cyclin E, a Potential Prognostic Marker in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, octubre de 1997. http://dx.doi.org/10.21236/ada341275.
Texto completoBaylin, Stephen B. Hypermethylation of AP-2Alpha as a Prognostic Marker for DCIS. Fort Belvoir, VA: Defense Technical Information Center, mayo de 2008. http://dx.doi.org/10.21236/ada494142.
Texto completoBaylin, Stephen. Hypermethylation of AP-2alpha as a Prognostic Marker for DCIS. Fort Belvoir, VA: Defense Technical Information Center, mayo de 2006. http://dx.doi.org/10.21236/ada456138.
Texto completoPettijohn, David. Oligosaccharide Markers for Prognosis of Low-Risk Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, septiembre de 1995. http://dx.doi.org/10.21236/ada306440.
Texto completoPettijohn, David. Oligosaccharide Markers for Prognosis of Low-Risk Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, septiembre de 1999. http://dx.doi.org/10.21236/ada382780.
Texto completo